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ultra-deep sequencingThere are conﬂicting data on the impact of low frequency HIV-1 drug-resistant mutants on the response of
ﬁrst-line highly active antiretroviral therapy (HAART), more speciﬁcally containing a NNRTI. As population
sequencing does not detect resistant viruses representing less than 15-25% of the viral population, more sen-
sitive techniques have been developed but still need clinical validation. We evaluated ultra-deep sequencing
(UDPS), recently more available and affordable, as a tool for the detection of HIV-1 minority species carrying
drug resistant mutation (DRM) in a clinical setting. A retrospective analysis of the reverse transcriptase (RT)
gene of plasma HIV-1 from 70 patients starting a NNRTI based regimen was performed. Minority populations
were deﬁned as representing >1% and b20% of the total viral population. Using UDPS, we could not conﬁrm
an association between the presence of low minority variants harbouring RT mutations at the start of therapy
and primary or secondary therapeutic failure.
© 2012 Elsevier Inc. All rights reserved.Introduction
Although antiretroviral therapy is highly successful in suppressing
HIV-1 infection, the efﬁcacy of ﬁrst line regimens can be reduced by
the presence of transmitted drug resistance. According to current
guidelines, NNRTI's are important components of antiretroviral ther-
apy in antiretroviral naive patients (http://www.aidsinfo.nih.gov/
guidelines). Antiretroviral drug resistance testing is recommended
in HIV-1 infected subjects before starting antiretroviral therapy to
guide the selection of appropriate ﬁrst line regimens (Hirsch et al.,
2008). In a previous study, the presence of pre-existing NNRTI-
resistant mutants detected by population sequencing was associated
with a 2.3 fold increased risk of virologic failure of ﬁrst line
efavirenz-based therapy (Kuritzkes et al., 2008). Other data showed
that antiretroviral drug resistance testing is cost-effective and im-
proves the virologic, immunologic and clinical outcomes of antiretro-
viral therapy (Gunthard et al., 1998). Current genotypic resistance
assays do not detect resistant viruses representing less than 15-25%
of the population (Palmer et al., 2005; Weinstein et al., 2001). More
sensitive techniques have been developed in order to increase sensi-
tivity for the resistant mutant virus minority population. On the one
hand, allele-speciﬁc RT-PCR leads to sensitive detection of individuale, Infectious Diseases and Psy-
e Pintelaan 185, B-9000 Gent,
Vandekerckhove).
rights reserved.drug-resistance mutations (Balduin et al., 2009; Goodman et al.,
2011; Halvas et al., 2006; Halvas et al., 2010; Johnson et al., 2007;
Metzner et al., 2005; Paredes et al., 2010; Peuchant et al., 2008). High-
ly sensitive parallel allele-speciﬁc sequencing (PASS), has been
shown to detect minor drug-resistant populations at 0.1 to 0.01%
levels, making use of the polony technique, but few clinical studies
in large patient cohorts have been published (Cai et al., 2007; Liu
et al., 2011; Wang et al., 2011). These two methods can only investi-
gate one predeﬁned mutation site at a time, are time consuming and
less applicable for a comprehensive analysis of larger genomic regions
of HIV in viral populations from many samples. Pyrosequencing tech-
nology was used early on to detect mutants on single positions
(O'Meara et al., 2001). Combined with a DNA bar coding system to in-
vestigate multiple positions and mutations, the detection limit could
be lowered to 5% of minor sequence variants (Hoffmann et al.,
2007). In the latest evolution, massive parallel picoliter-scale PCR am-
pliﬁcation and pyrosequencing of single DNA molecules (ultra-deep
pyrosequencing) is applied to detect minority variants in HIV popula-
tions up to 1% (Wang et al., 2007).
Clinical studies aiming at validation of these sensitive methodolo-
gies show inconsistent results. Some studies failed to show a signiﬁ-
cant correlation between the presence of minority variants and
subsequent virologic failure (Balduin et al., 2009; Jakobsen et al.,
2010; Metzner et al., 2011; Peuchant et al., 2008) while others
reported an overt correlation (Geretti et al., 2009; Goodman et al.,
2011; Halvas et al., 2010; Johnson et al., 2008; Paredes et al., 2010;
Simen et al., 2009). A recent systematic analysis of pooled clinical
Table 1
Characteristics of eligible patients according to response to NNRTI based antiretroviral treatment regimen.
Virologic Failure Virologic success (N=46) P value* Overall (N=53)
Primary (N=5) Secondary (N=2)
Age at diagnosis, median years (IQR) 29 (29-47) 31 35 (31-42) 0,87 35 (29-41)
Age at start HAART, median years (IQR) 39 (34-44) 32 39 (34-44) 0,59 39 (32-44)
Time from diagnosis to start NNRTI, median years (IQR) 2,9 (1,3-4,1) 0,9 1,0 (0,2-3,8) 0,39 1,2 (0,3-3,8)
Pre-NNRTI CD4 count, median cells/mm3 (IQR) 277 (229-386) 89 236 (188-313) 0,96 237 (188-316)
Pre-NNRTI viral load, median log 10 copies/ml (IQR) 5,00 (4,42-5,30) 5,38 4,73 (4,03-5,04) 0,10 4,81 (4,07-5,08)
NNRTI, N (%)
Efavirenz 3 (60) 1 (50) 30 (65,2) 0,69 34 (64,2)
Nevirapine 2 (40) 1 (50) 16 (34,8) 19 (35,8)
NRTI backbone, N (%)
3TC/ABC 1 (20,0) 2 (100) 3 (6,5) 6 (11,3)
3TC/AZT 1 (20,0) 10 (21,7) 11 (20,8)
3TC/D4T 8 (17,4) 8 (15,1)
3TC/TDF 3 (6,5) 3 (5,7)
AZT/3TC/ABC 1 (2,2) 1 (1,9)
TDF/FTC 3 (60) 21 (45,7) 24 (45,3)
* Virologic failure (N=7) versus virologic success (N=46).
IQR, interquartile range; HAART, Highly Active Antiretroviral Treatment; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase
inhibitor; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; TDF, tenofovir; FTC, emtricitabine.
Table 2
Prevalence of relevant drugresistance mutation (DRM) associated quasispecies in 53
analysed patient samples.
% DRM associated quasispecies
>20 >1 and b20 b1 0
no VF VF no VF VF no VF VF no VF VF
N= N= N= N= N= N= N= N=
Stanford score ≥5
A98G 1 1 45 6
L100I 2 5 39 7
K101E 6 1 40 6
V106A 1 46 6
V108I 1 4 1 41 6
V179F 1 45 7
E138A 2 1 4 39 7
NRTI mutation
M184V 1 45 7
Results are shown for patients who experienced virologic failure (VF) and for
successful therapy outcomes (no VF). The data are stratiﬁed in 4 categories (>20%,
>1% and b20%, b1% and 0%). Only the NNRTI mutations with Stanford score ≥5 and
detected in the analysis are represented. M184V is added as important NRTI mutation.
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resistance mutations and virologic failure with ﬁrst line NNRTI
based antiretroviral therapy (Li et al., 2011). However, all studies
have applied different detecting methodologies as well as different
sensitivity cut-offs for the interpretation of the data.
In this study, ultra-deep sequencing was used to assess the effect
of high and low frequency transmitted drug resistance (TDR) on viro-
logic responses to ﬁrst line NNRTI-based HAART regimens. From a pa-
tient population without known baseline genotypic resistance test
results, stored plasma samples collected immediately before starting
HAART were evaluated for the presence of TDR, with a cut-off above
the predeﬁned detection limit of 1%. This cut-off level was chosen to
avoid the high probability of technical artefacts below this threshold
(Gianella et al., 2011).
Results
The ultra-deep pyrosequencing was successful in all 70 samples.
Samples from patients on quadriple HAART (N=6), patients lost to
follow-up (N=3), and patients switched due to tolerance reasons
(N=8) were excluded from further analysis. In the group of 53 eligible
patients, 5 (9,4%) experienced primary virologic failure, 2 (3,7%) sec-
ondary virologic failure and 46 (86,8%) were virologically completely
suppressed at week 24 through 48. HAART contained most commonly
tenofovir/emtricitabine as NRTI backbone (n=24 [45,3%]) in combina-
tion with efavirenz (n=34 [64,2%]) or nevirapine (n=19 [35,8%]). Pa-
tient characteristics were balanced (Table 1). The median time course
from diagnosis to the start of HAART was 1,2 (IQR 0,3 – 3,8) year, with
a median CD4 count of 237 (IQR, 188–316) cells/mm3 at therapy
start. Virologic failure was deﬁned as primary when patients did not
achieve a viral load (VL) below 50 copies/mL within 24 weeks of start-
ing HAART and secondary when patients achieved a VL below 50 cop-
ies/mL within 24 weeks but experienced conﬁrmed virologic rebound
within 48 weeks according to Geretti et al. (2009).
The pyrosequencing yielded an average of 5602 reads per site per
patient sample. In total 593 unique sequences were identiﬁed, with an
average of 78 sequences per patient sample, of which 13 with a fre-
quency >1%. After performing ultra-deep sequencing analysis, only
genotyped drug resistance mutations (DRM) with a score of ≥5 in the
Stanford HIV Drug Resistance Database were taken into account (Rhee
et al., 2005). This criterion retained the relevant mutations A98G,
L100I, K101E/P/H/N/Q, K103N/R/S/T, V106A/M, V108I, E138A/K/Q/G,
V179D/E/F, Y181C/I/V/S, Y188C/H/L, G190A/C/E/Q/V/T for further eval-
uation. M184V/I as important NRTI resistancemutation is also reported.RT mutations as from amino acid 220 were not included for technical
reasons. Of the 53 patient samples that fulﬁlled the criteria, 36 (67,9%)
samples harbored any DRM associated quasispecies, of which 3 (6%)
samples contained relevant DRM in >20% of the detected quasispecies,
and 3 (6%) samples contained b20 and >1% relevant DRM (results are
depicted in Table 2). Samples below the predeﬁned threshold of 1%
were excluded from statistical analysis. The quasispecies of samples of
the ﬁrst group (DRM>20%)were also detected by population genotyp-
ing. In patients on triple ART with baseline plasma harbouringminority
DRM>1% and b20%, L100I (N=2); V108I (N=1), E138A (N=1)were
not associated with virologic failure. Fisher exact test could not demon-
strate an association between virologic failure or inadequate response
and the presence of minority variants. K103N and Y181C were not pre-
sent asminority DRM in our analysis. In four out of ﬁve cases of primary
treatment failure, there was evidence for non-adherence to the regi-
men. Two patient samples harboured wild type virus. In one patient
M184I and Y188Lwere selected and detected by population sequencing
at failure and suboptimal nevirapine levels were demonstrated. The
fourth patient with indication for non-adherence contained A98G
(52.6%), subsequently detected by population sequencing. The ﬁfth pa-
tient experiencing primary treatment failure was switched with a viral
RNA load of 203 copies/ml. There was no reported problem with
9P. Messiaen et al. / Virology 426 (2012) 7–11treatment adherence, and no drug monitoring levels were obtained.
The HIV sequence could not be ampliﬁed due to too low input. In two
patients who experienced secondary failure, one sample harboured
V106A (99.21%), conﬁrmed with population sequencing. In the second
patient, the viral load went up to 56 copies/ml (log 1,75) due to tran-
sient adherence problems and the analysis of the follow up sample
revealed an undetectable viral load on the same regimen.
Discussion
In a study by Wensing et al. (2005), assessing the baseline rate of
HIV-1 drug resistance using population sequencing, 1 in 10
antiretroviral-naive patients carried viruses with at least 1 DRM and
recently infected patients harboured resistant variants more often
than did chronically infected patients (13.5% vs. 8.7%; P=.006). As
new technologies become available, attention is now turning to
detecting and assessing the clinical impact of minority drug-
resistant HIV-1, the variants in the viral population present below
the 15 to 25% detection threshold of conventional bulk sequencing,
which can be important for ART selection. A range of different assays
has been developed to detect those low-frequency variants, as allele-
speciﬁc qPCR, multiplex-primer-extension PCR, single genome se-
quencing and ultra-deep sequencing. Some of these technologies
lack clinical validation.
An overview of all studies evaluating presence of HIV minority
species in relation to clinical outcome is presented in Table 3. The sys-
tematic comparison of these studies is not only challenged by the dif-
ferent technologies used or different sensitivity cut offs for
interpretation, but also by the heterogeneous patient populations in
terms of duration of infection and composition of preferred ﬁrst line
HAART. Moreover, analysis of the selected strain upon failing the
ﬁrst HAART regimen to conﬁrm its presence at baseline has not
been consistently performed. We evaluated the role of ultra-deep se-
quencing spanning a fragment from aminoacid 59 to 190, using a cut-
off for minority variant of 1%, on randomly selected samples of 70Table 3
Studies evaluating the presence of HIV minority variants harbouring drug resistance mutat
[Study] Patient
population (N)
DRM tested
(Paredes et al., 2010) EFV treatment start, no previous
NNRTI resistance (N=195)
K103N, Y181C
(Johnson et al., 2008) ART naïve patients with WT virus
(N=205) and one or more DRM
(N=303), case-control with EFV
treatment start (N=316)
L90M, M41L, K70R, K
Y181C, M184V, T215
(Geretti et al., 2009) NNRTI start, no previous DRM
testing (N=93)
K65R, K103N, Y181C
G190A
(Halvas et al., 2010) NNRTI start in NNRTI naïve (N=27)
and NNRTI experienced patients (N=76)
K103N, Y181C
(Simen et al., 2009) Patients starting NNRTI (N=86),
PI (N=108),
3-class ART (N=64)
All NNRTI, PI and NR
mutations
(Goodman et al., 2011) EFV start in therapy naïve patients,
no previous NNRTI resistance (N=485)
K103N
(Peuchant et al., 2008) Patients starting ART (N=127) K103N, M184V, L90M
(Balduin et al., 2009) Therapy-naïve patients starting
ART (N=159)
in RESINA cohort
K103N
(Jakobsen et al., 2010) Patients starting ART (N=61) M41L, K65R, K70R, Q
M184V, T215YF, T21
Y181C, G190ASE
(Metzner et al., 2011) Antiretroviral naive patients, initiating
therapy (N=146)
K65R, K103N, M184V
DRM=drug-resistance mutation; VF=virologic failure; UDPS=Ultra-Deep Pyrosequencin
transcriptase inhibitor.patients starting an NNRTI based regimen. Of the 53 patient samples
eligible for ﬁnal analysis, ﬁve patients experienced primary failure.
In line with a recently published pooled analysis, adherence problems
were identiﬁed in 4 on 5 patients experiencing primary treatment
failure (Li et al., 2011). So far, only one study with 86 patients in the
NNRTI arm evaluated ultra-deep sequencing as a technique to detect
minority variants harbouring DRM and found an association with
treatment failure (Simen et al., 2009). We could not conﬁrm this asso-
ciation. This might be due to the low number of treatment failure in
our study, and the potentially low number of minority NNRTI DRM
in a geographical region where protease inhibitors are preferentially
used. Besides that, it is important to notice that in the patient-group
experiencing primary treatment failure, the high prevalence of non-
adherence could mask the effect of previous existing DRM associated
minority variants. Ultra-deep sequencing is a powerful and promising
tool to detect DRM-associated minority variants, but sensitivity
thresholds and clinical relevance of variants below 1% still needs to
be determined. Except for the K103N, it stays difﬁcult to really pin-
point the value and the cut-off of each individual mutation: some var-
iants may retain their impact even if present at low frequency within
the quasispecies. A direct comparison between allele speciﬁc qPCR
and deep sequencing in clinical samples is lacking. As a ﬁrst step, a
prospective study offering comparative analysis of deep sequencing
and sensitive real-time PCR should evaluate the clinical feasibility of
these approaches in the future.
Methods
Study population
Seventy patients were selected from the Ghent University Hospital
clinical database. The patients were diagnosed HIV-positive from
1996 onward and started HAART with an efavirenz or nevirapine
based regimen between 1999 and 2007, without baseline genotypic
resistance testing. The ethnic background showed 16 (22%) patientsions in patients starting HAART.
Methods Results
Allele speciﬁc qPCR Y181C: association with risk of VF
in treatment adherent group (HR
3,45)
103N,
F/Y
Allele speciﬁc qPCR Association of VF with minority
DRM (P=0,0038)
, M184V, Population sequencing vs allele
speciﬁc qPCR
K103N: association with VF
(P=0,001)
Population sequencing vs single-
genome sequencing vs allele spe-
ciﬁc qPCR
K103N >1% associated with VF
TI Population sequencing vs UDPS Association of NNRTI DRM with VF
(HR 2,73)
Allele-speciﬁc qPCR K103N >2000copies/ml associated
with VF (OR 47.4 P=0.0006)
Allele-speciﬁc qPCR No inﬂuence of minority DRM on
therapy-response
Allele-speciﬁc qPCR Not signiﬁcant risk of treatment
failure with minority DRM (24% vs
15%), (P=0.3)
151M,
5D, K103N,
Multiplex-primer-extension PCR
(sensitivity DRM : 2%) vs
Population sequencing
All DRM: no signiﬁcant effect on
treatment outcome
Allele-speciﬁc qPCR No increase of VF at 12m and 24m
g; ART=anti-retroviral treatment; EFV=efavirenz; NNRTI=non-nucleoside reverse
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Patients had a minimum of 24 weeks of follow-up, and either experi-
enced virologic failure or maintained consistent virologic suppression
below 50 copies/mL without treatment changes. The viral load before
start ranged between 4x 103 and 10x 106 copies/mL.
Resistance testing by ultra-deep sequencing
The study was approved by the ethical committee of the Universi-
ty Hospital Ghent, Belgium. Samples were collected before starting
therapy and stored in aliquots at -80° C until further processing. Plas-
ma HIV-1 RNA was quantiﬁed with the Amplicor HIV Monitor v1.5
test (Roche Diagnostics Systems, Basel, Switzerland) with a lower
limit of detection of 50 RNA copies/ml. Viral RNA was extracted
from 500 μl of plasma (EasyMag, Biomérieux, France), reverse tran-
scribed to cDNA using the Accuscript HF RT enzyme (Agilent, Santa
Clara, USA) and random hexamers. The RT region encompassing
amino acids 59 to 190 was ampliﬁed in a nested PCR. In order to in-
crease the ampliﬁcation success, the outer PCR was performed with
a mixture of two primer pairs (HXB2 positions: outer forward
primers: 2700 - 2722 and 2693 - 2713; reverse forward primers:
3121 - 3146 and 3126 - 3151). Addition of barcode sequences to the
inner primers allowed the simultaneous processing of amplicons
originating from multiple individuals (HXB2 positions inner forward
primer: 2700 – 2722 and inner reverse primer: 3121 - 3146). Bar-
coded amplicons were pooled equimolarly and sequenced on the
GS-FLX instrument according to the manufacturer's standard ampli-
con sequencing protocol (454 Life Sciences, Roche, Branford, CT,
USA). The massive parallel sequencing experiment was designed to
reach on average a mutation detection sensitivity of 1%, whereby a
mutation was reported as “detected” if it was observed in at least
50 individual reads (as recommended by Roche). This implies an av-
erage coverage of the amplicon by 5,000 sequence reads. To reach
that goal, the processing of the samples required three GS-FLX runs,
each generating on average 63 million bases of sequence in 261,000
individual reads. Amplicons were sequenced from both ends (for-
ward and reverse) revealing a median sequence read length of 258
bp. The Amplicon Variant Analyzer (AVA) software (Roche) was
used for read mapping and calculating variant frequencies at each nu-
cleotide position relative to the sequence of HIV-1 reference strain
HXB2. An average coverage of 5,602 reads per position was obtained.
Subsequent to the variant detection analysis by AVA software, which
comprises error correction for carry forward and incomplete exten-
sion errors (two major error types characteristic for the 454 pyrose-
quencing technology), the presence of all relevant mutations was
manually veriﬁed by inspection of the individual ﬂowgrams at these
positions. Further technical details (primer design, handling of PCR
induced errors) and validation of the HIV-1 RT deep sequencing
assay have been described by Vandenbroucke et al. (2011), demon-
strating high intra- and inter-run reproducibility with correlations
and concordances >0.97 for the detection of sequence variants pre-
sent at frequencies above 1%.
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